Impact of an Endoscopic Treatment of the Line Z on the Gastronomic Recurrence and the Gastro- Esophageal Reflux Disease in the Care of the Adenocarcinoma of Barrett's Oesophagus
NCT ID: NCT03278327
Last Updated: 2021-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2017-06-27
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This metaplasia can evolve in low grade dysplasia LGD) , high grade dysplasia (HGD) then invasive adenocarcinoma.
The treatment of the HGD of the Barrett is the endoscopic treatment. It is about a superficial treatment of tumor without ganglionar invasion by definition.
The endoscopic treatment of the Barrett began in the 2000s, and showed its long-term efficiency.
The studied factors of recurrences are the length of the Barrett, the influence of the eradication completes of the Barrett besides the eradication of the dysplasia, as well as the duration of spacing of the procedures. An anatomical zone is particularly delicate to treat. It is about the anatomical junction between the oesophagus and the stomach appointed junction oeso-gastric or cardia or line Z.
This almost virtual zone is the site of most of the recurrence. The first cause of the oesophagus of Barrett and of its transformation in HGD is the reflux.
This reflux can be handled by medicinal action inhibitor of the pump with proton (PPI) or by surgery (hemi-fundo plicator). This reflux is probably the cause of the long-term recurrence found in the literature.
The surgery is a good treatment of the reflux with however unsatisfactory long-term results. On the other hand, the surgery is little used after endoscopic treatment of a HGD not to compromise the surveillance and the detection of a second offense potentially masked in the surgical fundo-plicator. The endoscopic treatment of the expensive ebb because of the based necessary material too on a fundo-plicator is complicated with use in reason also of his cost.
The medical treatment by PPI for life, besides his duration and thus the potential hardness for the patient, presents long-term complications recently described.
Effects on the appearance of gastric precancerous lesion is not certain, but this association with an osteoporosis is more proved true.
The PPI could also be a etiologic factor of chronic renal insufficiency and insanity.
An endoscopic treatment describes by Inoue " Anti-Reflux Mucosectomy " ( ARMS) allows to decrease the gastro- esophageal reflux disease.
This treatment is an equivalent of on treatment of the line Z which would at the same time allow to make sure of the decrease of recurrence on the line Z by complete treatment of this one and to handle the reflux of these patients.
In this experimental series, 10 patients having made this endoscopic treatment were able to stop their treatment by PPI.
The purpose of this study will be to make sure of the efficiency of the endoscopic treatment of the reflux by it on treatment of this line Z while decreasing the frequent recurrences on this line Z.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ESD for the Treatment of Early Barrett's Neoplasia
NCT02583087
High Resolution Virtual Chromoendoscopy Versus Seattle Protocol for the Surveillance of Barrett's Esophagus
NCT05229783
Long Term Barrett's Endoscopic Mucosal Resection Study
NCT02200250
Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus
NCT04818476
Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus
NCT00586989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endoscopic resection
Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.
Endoscopic resection treatment
Endoscopic resection at month 2 and month 4
System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.
The device the most used in this case is the system COOK Medical Duett of Laboratories.
The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.
The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.
Endoscopic resection treatment
Endoscopic resection at month 2 and month 4
System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.
The device the most used in this case is the system COOK Medical Duett of Laboratories.
The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.
The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High grade dysplasia or superficial Barrett's oesophagus adenocarcinoma diagnosis,
* Written informed consent,
* Affiliation to Social Security System.
Exclusion Criteria
* Surgical histories treatment of gastro- esophageal reflux disease,
* Woman pregnant or susceptible to the being,
* Patients deprived of liberty or placed Under the authority of a tutor,
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule,
* Contraindications to the endoscopic procedure.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Paoli-Calmettes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CAILLOL Fabrice, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Paoli-Calmettes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GENRE
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Institut PAOLI-CALMETTES
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B-ARMS-IPC 2016-017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.